Shareholders Equity: The sum of preferred and common equity items.
Regentis Biomaterials Ltd. (RGNT) had Shareholders Equity of $4.74M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-13.69M |
|
-- |
|
-- |
|
$6.97M |
|
$-6.97M |
|
$-6.68M |
|
$-13.65M |
|
$-13.65M |
|
$-13.65M |
|
$-13.65M |
|
$-13.65M |
|
$-13.65M |
|
$-6.97M |
|
$-6.97M |
|
0.57M |
|
0.57M |
|
$-24.16 |
|
$-24.16 |
|
| Balance Sheet Financials | |
$7.62M |
|
-- |
|
-- |
|
$7.62M |
|
$2.87M |
|
-- |
|
-- |
|
$2.87M |
|
$4.74M |
|
$4.74M |
|
|
Shareholders Equity |
$4.74M |
5.18M |
|
| Cash Flow Statement Financials | |
$-1.38M |
|
-- |
|
$8.52M |
|
$0.23M |
|
$7.38M |
|
$7.15M |
|
$7.04M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.65 |
|
-- |
|
-- |
|
-- |
|
0.25 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.38M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-287.69% |
|
-287.69% |
|
-179.15% |
|
-287.69% |
|
$0.92 |
|
$-2.43 |
|
$-2.43 |
|